Literature DB >> 12030914

The neuro-cardio-endocrine response to acute subarachnoid haemorrhage.

Eric A Espiner1, Robert Leikis, Richard D Ferch, Martin R MacFarlane, Janusz A Bonkowski, Christopher M Frampton, A Mark Richards.   

Abstract

OBJECTIVE: Whereas cardiac hormones increase after subarachnoid haemorrhage (SAH), and may contribute to sodium wastage and hyponatraemia, there is controversy concerning the relative roles of atrial natriuretic peptide (ANP) vs. brain natriuretic peptide (BNP) and the factors initiating their secretion. Noting previous work linking stress hormone responses with cardiac injury after SAH, we have studied responses in stress hormones, markers of cardiac injury and the temporal changes in ANP and BNP and related them to changes in sodium status post ictus and during recovery from acute SAH. DESIGN, PATIENTS, MEASUREMENTS: Eighteen patients with verified SAH of variable severity were studied in a single unit for a 14-day period post ictus under controlled conditions of sodium and fluid intake. All received a standardized protocol of daily dexamethasone and nimodipine throughout the study. Severity was graded using criteria of Hess and Hunt at admission. Stress hormones (AVP, catecholamines and admission plasma cortisol), markers of cardiac injury (ECG and daily plasma troponin T) and cardiac hormones (ANP and BNP) were measured daily and related to severity, plasma sodium and renin-aldosterone activity. Hormone levels (ANP, BNP and endothelin) in cerebrospinal fluid (CSF) were also measured in nine patients.
RESULTS: Intense neurohormonal activation (AVP, cortisol and catecholamines) at admission was associated with increased levels of both plasma ANP and BNP whereas levels in CSF were unaffected. In individual patients plasma levels of ANP and BNP were strongly correlated (P < 0.001). Cardiac events (abnormal ECG and/or elevated troponin) occurred in six of seven patients graded severe but neither stress hormones nor cardiac peptides differed significantly in patients with mild (n = 11) vs. severe (n = 7) SAH. During the course of a progressive fall in plasma sodium concentration (P = 0.001), there was a delayed activation of renin-aldosterone which was inversely correlated with declining levels of plasma ANP/BNP (P < 0.002).
CONCLUSIONS: Excessive secretion of both ANP and BNP occurs in all patients after acute subarachnoid haemorrhage and is unrelated to severity, stress hormone activation or markers of cardiac injury. Inhibition of renin-aldosterone by cardiac hormones may impair renal sodium conservation and contribute to developing hyponatraemia. In the absence of evidence for activation of natriuretic peptides within the brain, the prompt and consistent increase in both ANP and BNP strongly supports the view that the heart is the source of increased natriuretic peptide secretion after acute subarachnoid haemorrhage.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12030914     DOI: 10.1046/j.1365-2265.2002.01285.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  30 in total

1.  Brain natriuretic peptide concentrations after aneurysmal subarachnoid hemorrhage: relationship with hypovolemia and hyponatremia.

Authors:  Sanne M Dorhout Mees; Reinier G Hoff; Gabriel J E Rinkel; Ale Algra; Walter M van den Bergh
Journal:  Neurocrit Care       Date:  2011-04       Impact factor: 3.210

2.  Development of contrast-induced nephropathy in subarachnoid hemorrhage: a single center perspective.

Authors:  Bappaditya Ray; Kim L Rickert; Babu G Welch; Jonathan A White; Daniel R Klinger; Benjamin P Boudreaux; Brett A Whittemore; Eugene Gu
Journal:  Neurocrit Care       Date:  2013-10       Impact factor: 3.210

3.  Randomized, double-blind trial of the effect of fluid composition on electrolyte, acid-base, and fluid homeostasis in patients early after subarachnoid hemorrhage.

Authors:  Laura Lehmann; Stepani Bendel; Dominik E Uehlinger; Jukka Takala; Margaret Schafer; Michael Reinert; Stephan M Jakob
Journal:  Neurocrit Care       Date:  2013-02       Impact factor: 3.210

4.  Perioperative serum brain natriuretic peptide and cardiac troponin in elective intracranial surgery.

Authors:  Francesco Ruggieri; Marco Gemma; Maria Rosa Calvi; Elisa Nicelli; Andrea Agarossi; Luigi Beretta
Journal:  Neurocrit Care       Date:  2012-12       Impact factor: 3.210

Review 5.  Impact of echocardiographic wall motion abnormality and cardiac biomarker elevation on outcome after subarachnoid hemorrhage: a meta-analysis.

Authors:  Limin Zhang; Bing Zhang; Sihua Qi
Journal:  Neurosurg Rev       Date:  2018-05-26       Impact factor: 3.042

6.  Controversies and evolving new mechanisms in subarachnoid hemorrhage.

Authors:  Sheng Chen; Hua Feng; Prativa Sherchan; Damon Klebe; Gang Zhao; Xiaochuan Sun; Jianmin Zhang; Jiping Tang; John H Zhang
Journal:  Prog Neurobiol       Date:  2013-09-25       Impact factor: 11.685

7.  Insulin like growth factor-I in acute subarachnoid hemorrhage: a prospective cohort study.

Authors:  Stepani Bendel; Timo Koivisto; Olli-Pekka Ryynänen; Esko Ruokonen; Jarkko Romppanen; Vesa Kiviniemi; Ari Uusaro
Journal:  Crit Care       Date:  2010-04-28       Impact factor: 9.097

Review 8.  Interpretation and use of natriuretic peptides in non-congestive heart failure settings.

Authors:  Shih-Hung Tsai; Yen-Yue Lin; Shi-Jye Chu; Ching-Wang Hsu; Shu-Meng Cheng
Journal:  Yonsei Med J       Date:  2010-02-12       Impact factor: 2.759

9.  Mitigation of murine focal cerebral ischemia by the hypocretin/orexin system is associated with reduced inflammation.

Authors:  Xiaoxing Xiong; Robin E White; Lijun Xu; Liya Yang; Xiaoyun Sun; Bende Zou; Conrado Pascual; Takeshi Sakurai; Rona G Giffard; Xinmin Simon Xie
Journal:  Stroke       Date:  2013-01-24       Impact factor: 7.914

Review 10.  Hyponatremia and brain injury: historical and contemporary perspectives.

Authors:  Matthew A Kirkman; Angelique F Albert; Ahmed Ibrahim; Doris Doberenz
Journal:  Neurocrit Care       Date:  2013-06       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.